scholarly journals Role of the β3 Integrin Subunit in Human Primary Melanoma Progression

1998 ◽  
Vol 153 (5) ◽  
pp. 1347-1351 ◽  
Author(s):  
Richard E.B. Seftor
Keyword(s):  
Primary Melanoma ◽  
Integrin Subunit ◽  
Melanoma Progression ◽  
Β3 Integrin

Differential expression of insulin like growth factor binding protein-4 (IGFBP4) in melanoma progression

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 8557-8557
Author(s):  
J. Z. Yu ◽  
H. Yee ◽  
M. Warycha ◽  
P. Christos ◽  
R. Shapiro ◽  
...  
Keyword(s):  
Primary Melanoma ◽  
Tissue Expression ◽  
Diagnostic Systems ◽  
Melanoma Tumor ◽  
Melanoma Progression ◽  
School Of Medicine ◽  
Wilcoxon Rank Sum Test ◽  
Stage Ia ◽  
Melanoma Patients

8557 Background: Members of the IGFBP family are thought to regulate tumor progression through both IGF-dependent and independent mechanisms. Moreover, IGFBPs may exhibit distinct functions depending on whether they are present locally in tissue or systemically. Our preclinical data suggest that IGFBP4 serves as an endogenous inhibitor of angiogenesis and melanoma tumor growth. To examine the clinical validity of our observations, we compared IGFBP4 expression in tissue and sera in primary melanoma patients with a low risk of metastases versus patients with established metastatic disease. Methods: Eighty-nine melanoma patients (primary stage IA, n=57; metastatic, n=32; 44 M, 45 F; Median Age=56) prospectively enrolled in the Interdisciplinary Melanoma Cooperative Group at the NYU School of Medicine were studied. IGFBP4 protein expression in tumors was assessed in 83 patients using goat anti-human IGFBP4 antibody (R&D Systems) in an immunohistochemical assay. For each case, the percentage of tumor cells that stained positively was estimated. IGFBP4 concentration in the serum was measured in 64 patients by an ELISA assay (Diagnostic Systems Laboratories, Inc.). Fifty-eight patients had both sera and tumor specimens available for correlation. Results: The median IGFBP4 expression in tumor specimens from primary patients was 70% compared to 5% in metastatic patients (P=0.002, Wilcoxon rank-sum test). The median concentration of IGFBP4 in sera was 43.8 ng/ul in primary patients versus 41.0 ng/ul in metastatic patients (P=0.83). A weak association between IGFBP4 expression in tissue and IGFBP4 shedding in sera was observed (Spearman correlation coefficient=0.16, P=0.24) in the 58 cases with both sera and tissue available. Conclusions: Our data demonstrate that IGFBP4 expression in melanoma clinical specimens decreases in the progression from primary to metastatic melanoma, consistent with its potential role as an inhibitor of angiogenesis. Data also suggest that IGFBP4 tissue expression may be more clinically relevant than its sera shedding. Future studies using a larger sample size and extended follow up are needed to further define the role of IGFBP4 in melanoma progression. No significant financial relationships to disclose.

scholarly journals The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma – an immunohistochemical study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Satu Salmi ◽  
Anton Lin ◽  
Benjamin Hirschovits-Gerz ◽  
Mari Valkonen ◽  
Niina Aaltonen ◽  
...  
Keyword(s):  
T Cells ◽  
Prognostic Factors ◽  
Regulatory T Cells ◽  
Tumor Cells ◽  
Immune Cells ◽  
Positive Association ◽  
Tumor Stage ◽  
Melanoma Cells ◽  
Melanoma Progression

Abstract Background FoxP3+ Regulatory T cells (Tregs) and indoleamine-2,3-dioxygenase (IDO) participate in the formation of an immunosuppressive tumor microenvironment (TME) in malignant cutaneous melanoma (CM). Recent studies have reported that IDO expression correlates with poor prognosis and greater Breslow’s depth, but results concerning the role of FoxP3+ Tregs in CM have been controversial. Furthermore, the correlation between IDO and Tregs has not been substantially studied in CM, although IDO is known to be an important regulator of Tregs activity. Methods We investigated the associations of FoxP3+ Tregs, IDO+ tumor cells and IDO+ stromal immune cells with tumor stage, prognostic factors and survival in CM. FoxP3 and IDO were immunohistochemically stained from 29 benign and 29 dysplastic nevi, 18 in situ -melanomas, 48 superficial and 62 deep melanomas and 67 lymph node metastases (LNMs) of CM. The number of FoxP3+ Tregs and IDO+ stromal immune cells, and the coverage and intensity of IDO+ tumor cells were analysed. Results The number of FoxP3+ Tregs and IDO+ stromal immune cells were significantly higher in malignant melanomas compared with benign lesions. The increased expression of IDO in melanoma cells was associated with poor prognostic factors, such as recurrence, nodular growth pattern and increased mitotic count. Furthermore, the expression of IDO in melanoma cells was associated with reduced recurrence˗free survival. We further showed that there was a positive correlation between IDO+ tumor cells and FoxP3+ Tregs. Conclusions These results indicate that IDO is strongly involved in melanoma progression. FoxP3+ Tregs also seems to contribute to the immunosuppressive TME in CM, but their significance in melanoma progression remains unclear. The positive association of FoxP3+ Tregs with IDO+ melanoma cells, but not with IDO+ stromal immune cells, indicates a complex interaction between IDO and Tregs in CM, which demands further studies.

scholarly journals 588 Essential role of periostin in inflammation-associated melanoma progression in human and mouse

2017 ◽  
Vol 137 (10) ◽  
pp. S293
Author(s):  
F. Ohno ◽  
T. Nakahara ◽  
M. Nakahara ◽  
S. Nunomura ◽  
K. Izuhara ◽  
...  
Keyword(s):  
Essential Role ◽  
Melanoma Progression ◽  
Human And Mouse

ROLE OF NUCLEAR FACTOR κB IN MELANOMA PROGRESSION.

2007 ◽  
Vol 55 (1) ◽  
pp. S158
Author(s):  
A. M. DeLuca ◽  
B. Ryu ◽  
R. Alani
Keyword(s):  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Melanoma Progression

Potential role of CCL27 and CCR10 expression in melanoma progression and immune escape

2006 ◽  
Vol 42 (8) ◽  
pp. 1181-1187 ◽  
Author(s):  
Oriana Simonetti ◽  
Gaia Goteri ◽  
Guendalina Lucarini ◽  
Alessandra Filosa ◽  
Tiziana Pieramici ◽  
...  
Keyword(s):  
Potential Role ◽  
Immune Escape ◽  
Melanoma Progression ◽  
Ccr10 Expression

scholarly journals Exome sequencing in primary melanoma identifies novel drivers of melanoma progression

2015 ◽  
Vol 13 (Suppl 1) ◽  
pp. P2
Author(s):  
Valentina Montagnani ◽  
Matteo Benelli ◽  
Alessandro Apollo ◽  
Silvia Pandolfi ◽  
Gianni Gerlini ◽  
...  
Keyword(s):  
Exome Sequencing ◽  
Primary Melanoma ◽  
Melanoma Progression

scholarly journals Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations

Cancers ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 2284
Author(s):  
Serena Stamatakos ◽  
Giovanni Luca Beretta ◽  
Elisabetta Vergani ◽  
Matteo Dugo ◽  
Cristina Corno ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Metastatic Melanoma ◽  
Mutant Cell ◽  
Braf Inhibitor ◽  
Cancer Cell Line ◽  
Melanoma Cells ◽  
Melanoma Progression ◽  
Increased Sensitivity ◽  
Resistant Cells

Metabolic changes promoting cell survival are involved in metastatic melanoma progression and in the development of drug resistance. In BRAF-inhibitor resistant melanoma cells, we explored the role of FASN, an enzyme involved in lipogenesis overexpressed in metastatic melanoma. Resistant melanoma cells displaying enhanced migratory and pro-invasive abilities increased sensitivity to the BRAF inhibitor PLX4032 upon the molecular targeting of FASN and upon treatment with the FASN inhibitor orlistat. This behavior was associated with a marked apoptosis and caspase 3/7 activation observed for the drug combination. The expression of FASN was found to be inversely associated with drug resistance in BRAF-mutant cell lines, both in a set of six resistant/sensitive matched lines and in the Cancer Cell Line Encyclopedia. A favorable drug interaction in resistant cells was also observed with U18666 A inhibiting DHCR24, which increased upon FASN targeting. The simultaneous combination of the two inhibitors showed a synergistic interaction with PLX4032 in resistant cells. In conclusion, FASN plays a role in BRAF-mutated melanoma progression, thereby creating novel therapeutic opportunities for the treatment of melanoma.

Sign in / Sign up

Export Citation Format

Share Document